Fig. 8

ELOA mediates DLGAP1-AS2-driven CRC growth and metastasis. A-B Cell proliferation and colony formation abilities in WT and Trim21-KO HCT116 cells transfected with plasmids of DLGAP1-AS2 and ELOA. C Cell migration and invasion abilities in WT and Trim21-KO HCT116 cells transfected with plasmids of DLGAP1-AS2 and ELOA. D GSEA pathway enrichment analyses using the differentially expressed genes (DRGs) potentially affected by DLGAP1-AS2 and ELOA. DRGs were identified in DLGAP1-AS2-silenced and ELOA-overexpressing HCT116 cells using RNA-seq. E Validation of selected DRGs in HCT116 cells transfected with the siRNAs or plasmids of DLGAP1-AS2 and ELOA. F LHPP mRNA expression was detected by qRT-PCR in ELOA-overexpressing HCT116 cells. G The relative luciferase activity of LHPP promoter in ELOA-overexpressing HCT116 cells. H The recruitment of ELOA to the indicated regions of the LHPP promoter was determined by ChIP-PCR. IgG was used as the negative control. I The potential binding motif of ELOA was validated by luciferase assays. Mut: the mutant LHPP promoter lacking of the putative binding motif of ELOA. J Correlation analyses between DLGAP1-AS2 and LHPP. K The effect of DLGAP1-AS2/ELOA on the AKT pathway (pAKT at Ser473)